Related references
Note: Only part of the references are listed.Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity
Lihui Wang et al.
CELL DEATH & DISEASE (2017)
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
L. Wang et al.
CELL DEATH & DISEASE (2016)
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
Takuya Sakamoto et al.
PLOS ONE (2016)
Acetyl-CoA and the regulation of metabolism: mechanisms and consequences
Lei Shi et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
Igor Tsaur et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Sequencing of agents in castration-resistant prostate cancer
David Lorente et al.
LANCET ONCOLOGY (2015)
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials
Dharam Kaushik et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Protein acetylation as a means to regulate protein function in tune with metabolic state
Lei Shi et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Regulation of SOD2 and β-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells
Denglu Zhang et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2014)
p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles
Jasmine Kaur et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells
Yongqing Liu et al.
CANCER LETTERS (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Marchantin M: a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells
H. Jiang et al.
CELL DEATH & DISEASE (2013)
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells
P. Peixoto et al.
CELL DEATH AND DIFFERENTIATION (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Histone acetylation resulting in resistance to methotrexate in choroid plexus cells
Preethi Prasad et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
Masashi Takeda et al.
PROSTATE (2007)
Endoplasmic reticulum stress-induced cell death mediated by the proteasome
L. Egger et al.
CELL DEATH AND DIFFERENTIATION (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
MTOR, translation initiation and cancer
Y. Mamane et al.
ONCOGENE (2006)
Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice
AL Zhang et al.
CANCER LETTERS (2006)
Coping with stress: eIF2 kinases and translational control
RC Wek et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
ATP citrate lyase inhibition can suppress tumor cell growth
G Hatzivassiliou et al.
CANCER CELL (2005)
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
LW Chen et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group
TYH Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors
MD Castro-Galache et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
LM Butler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure
AN Makarovskiy et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells
AA Ruefli et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
